Riskpilot← Back to searchSign inGet full accessAsahi Kasei Pharma Denmark A/S
A/SActiveCVR 40948074Gdanskgade 18Manufacture of pharmaceutical preparations · NACE 2120Est. 2019— employees
Revenue 2025
DKK -639K
-16% vs 2024
EBITDA margin
100.0%
+16% vs 2024
Equity ratio
99.4%
Financial strength
Net profit 2025
DKK 26,1M
+2% vs 2024
| Revenue | DKK -639K | -16% |
| EBITDA | DKK -639K | +16% |
| Net profit | DKK 26,1M | +2% |
| Total assets | DKK 983M | +3% |
| Equity | DKK 977,5M | +3% |
| Employees | — | — |
Legal name
Asahi Kasei Pharma Denmark A/S
CVR number
40948074
Legal form
Aktieselskab
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
21. november 2019
Share capital
DKK 901.599.600
Employees
—
VAT registered
No
Audit selected
Yes
Last report
2025-03-31
Financial year
January – December
Signatory rights
Selskabet tegnes af et bestyrelsesmedlem.
Company purpose
Selskabets formål er direkte eller via besiddelse af kapitalandele i andre selskaber at drive udvikling, produktion og handel relateret til pharma-virksomhed samt anden virksomhed, der efter bestyrelsens skøn er forbundet dermed.
Address
Gdanskgade 18
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | -3.438 | -1.217 | -941 | -758 | -639 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -3.438 | -1.217 | -941 | -758 | -639 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 |
| EBIT | -3.438 | -1.217 | -941 | -758 | -639 |
| Net financials | -621.557 | 7.493 | 24.568 | 33.677 | 34.090 |
| Profit before tax | -624.995 | 6.276 | 23.627 | 32.919 | 33.451 |
| Tax | 498 | 1.606 | 5.395 | 7.426 | 7.379 |
| Net profit | -625.493 | 4.670 | 18.233 | 25.493 | 26.073 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 8.389.485 | 912.639 | 930.142 | 957.054 | 982.981 |
| Equity | 8.386.903 | 907.660 | 925.893 | 951.386 | 977.458 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 2.582 | 4.979 | 4.249 | 5.669 | 5.523 |
| Total debt | 2.582 | 4.979 | 4.249 | 5.669 | 5.523 |
EBITDA margin
-63857300.0%
This company
15.8%
Market median
-404160227% vs market
20212025
Equity ratio
99.4%
This company
38.2%
Market median
+160% vs market
20212025
Return on equity
2.7%
This company
18.4%
Market median
-85% vs market
20212025
Net profit margin
2607277100.0%
This company
8.1%
Market median
+32188606073% vs market
20212025
Asset turnover
-0.00×
This company
1.12×
Market median
-100% vs market
20212025
Debt / equity
0.01×
This company
0.62×
Market median
+98% vs market
20212025
- Annual report 2025Filed via CVR / Virk · Period 2024-04-01 – 2025-03-31
- Annual report 2024Filed via CVR / Virk · Period 2023-04-01 – 2024-03-31
- Annual report 2023Filed via CVR / Virk · Period 2022-04-01 – 2023-03-31
- Annual report 2022Filed via CVR / Virk · Period 2021-04-01 – 2022-03-31
- Annual report 2021Filed via CVR / Virk · Period 2019-11-21 – 2021-03-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
JH Founder | Founder | 2019 |
DM Management | Management | 2019 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2025 | |
| Chairman | 2019 | |
| Former (1) | ||
| Board of Directors | 2019 – 2025 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100% | 100% | 2019 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Asahi Kasei Pharma Denmark A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jacob Hjortshøj | Founder | 0 companies |
| Daisuke Matsuo | Management | 0 companies |
| Kenro Yuzaki | Board of Directors | 0 companies |
| Matthew Ryan Dumont | Board of Directors | 0 companies |
| Masaya Etoh | Chairman | 0 companies |